uniQure

uturn
Biotech

uniQure's gene therapy for Huntington's hits FDA roadblock

UniQure said the FDA backtracked on their agreement by deeming the phase 1/2 data based on an external control inadequate to support an application.
Angus Liu Nov 3, 2025 10:03am
business targets illustration

uniQure plans FDA push after Huntington's gene therapy trial win

Sep 24, 2025 9:20am
parachute sunset paragliding chutes

Takeda taps new head of US oncology business—Chutes & Ladders

Aug 2, 2024 8:30am
los angeles summer heatwave

3 biotechs try to beat the summer heat by shedding staff

Aug 1, 2024 10:49am
maze unravel find navigate direction path

uniQure's interim data shows gene therapy slows Huntington’s

Jul 9, 2024 9:25am
tunnel light dark climb stuck hole

uniQure Huntington's gene therapy data 'on the favorable side'

Dec 19, 2023 11:28am